Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CDC25A | P30304 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479222 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479388 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479198 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL672371 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL671456 | 1.00 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619726 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL4619498 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479563 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL479610 | 0.97 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL | |
| SCHEMBL1576782 | 0.96 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2NR5A2NR5A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 882 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090423-A1 | UNIVERSAL LNP COMPOSITIONS | PRIME MEDICINE, INC (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4638461-A1 | DUAL LIPID STRUCTURES | Turn Biotechnologies, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025151735-A1 | IONIZABLE LIPIDS FOR DRUG DELIVERY | CARNEGIE MELLON UNIVERSITY (US) | 2025-07-17 | — | — | WO | claimed |
| CN-119998259-A | Lipid structures and compositions comprising the same | 特恩生物技术公司 | 2025-05-13 | — | — | CN | claimed |
| WO-2025090663-A1 | NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME | GENERATION BIO CO. (US) | 2025-05-01 | — | — | WO | claimed |
| WO-2025075477-A1 | NANODISC COMPRISING ANGIOTENSIN-CONVERTING ENZYME 2 AND FC FRAGMENT, AND USE THEREOF | 엠브릭스 주식회사 | 2025-04-10 | — | — | WO | claimed |
| WO-2025059332-A1 | LIPID FORMULATION USING MULTI-COMPONENT CONDENSATION REACTION AND LIPID NANOPARTICLES MADE USING THE SAME | OREGON STATE UNIVERSITY (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025057230-A1 | DELIVERY SYSTEM AND METHOD OF PREPARATION THEREOF | MICRO CRISPR PVT. LTD. (IN) | 2025-03-20 | — | — | WO | claimed |
| EP-4475824-A1 | IMMUNOGENIC MRNA DELIVERY VEHICLES | Corner Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | claimed |
| EP-4466345-A2 | TRANSMEMBRANE RECEPTOR GENE EDITING | Orthobio Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | claimed |
| WO-2005063205-A2 | INJECTABLE PHOSPHATIDYLCHOLINE PREPARATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-07-14 | — | — | WO | claimed |
| WO-2005041866-A2 | PHARMACEUTICAL FORMULATIONS, METHODS AND DOSING REGIMENS FOR THE TREATMENT AND PREVENTION OF ACUTE CORONARY SYNDROMES | ESPERION THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| EP-1471885-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION | Elan Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003059280-A2 | EFFICIENT LIPOSOMAL ENCAPSULATION | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| WO-2003057190-A1 | EFFICIENT NUCLEIC ACID ENCAPSULATION INTO MEDIUM SIZED LIPOSOMES | ELAN PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| EP-1320631-A2 | USE OF NONVIABLE PARTICLES COMPRISING AN INTERNAL CONTROL (IC) NUCLEIC ACID | Nasjonalt folkehelseinstitutt. (NO) | 2003-06-25 | — | — | EP | claimed |
| EP-1185872-A1 | METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS | The Government of the United States represented by the Secretary of the Department of Health and Human Services (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2002018635-A2 | USE OF NONVIABLE PARTICLES COMPRISING AN INTERNAL CONTROL (IC) NUCLEIC ACID | STATENS INSTITUTT FOR FOLKEHELSE (NO) | 2002-03-07 | — | — | WO | claimed |
| WO-2000075666-A1 | METHOD FOR DETECTING SYPHILIS USING SYNTHETIC ANTIGENS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-12-14 | — | — | WO | claimed |
| WO-1998049281-A1 | METHODS FOR TREATING VIRAL INFECTIONS | NEW YORK BLOOD CENTER, INC. (US) | 1998-11-05 | — | — | WO | claimed |